GB 1 - Geneva Biotech
Alternative Names: GB1 - Geneva BiotechLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Geneva Biotech
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus spike glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronavirus infections; COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Coronavirus-infections in Switzerland
- 28 Oct 2024 No recent reports of development identified for research development in COVID-2019-infections in Switzerland
- 06 Oct 2020 Early research in Coronavirus infections in Switzerland (unspecified route) (Geneva Biotech pipeline,